-+ 0.00%
-+ 0.00%
-+ 0.00%

Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule

PUBT·05/05/2026 12:03:11
Listen to the news
Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule
  • NIAID to fully fund up to USD 7 million of in vivo studies to support Entolimod BLA filing under FDA Animal Rule pathway.
  • Program uses an FDA-precedent study protocol previously accepted for an acute radiation syndrome countermeasure, cutting design risk for BLA-enabling work.
  • Studies to be run at Armed Forces Radiobiology Research Institute, with NIAID set to co-navigate FDA submission upon favorable results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL51239) on May 05, 2026, and is solely responsible for the information contained therein.